We monitored the effectiveness of @entity706 therapy by measuring the serum levels of soluble @entity1759 std (sCD44std) and soluble CD44v6 (sCD44v6). Furthermore, we measured the level of soluble interleukin 2 receptor (sIL-2R). A total of 24 @entity1 with @entity1893 were enrolled. sCD44std, sCD44v6, and sIL-2R on serum were measured using ELISA system. In all @entity1 , only the sIL-2R level decreased significantly following therapy. However, an analysis of CR and PR showed that the degree of decrease in the sCD44std level was significantly greater than that in the sIL-2R level. Furthermore, among the CS IV cases, only the @entity1759 std level decreased significantly after therapy. These findings suggest that the level of serum sCD44std reflects clinical pathology more closely than the level of serum sIL-2R in CS IV @entity1 and those who respond well to therapy. Moreover, when T-cell and @entity1892 were analyzed separately, the levels of sCD44std and sIL-2R decreased significantly after therapy in @entity1 with @entity1892 , and the degree of decrease in the sCD44std level was very significant with a p-value of 0.0003. This suggests that when sCD44std is used as an index of treatment, it more closely reflects the treatment of @entity1892 . Level of serum sCD44std should prove to be a useful marker for assessing the effectiveness of @entity706 therapy.

Clinical significance of serum XXXX measurement in @entity706 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity1759 :: ('960', 'Gene') :: ['CD44'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphomas'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"]
@entity1759 :: (960,Gene) :: ['CD44']
